Ocular Therapeutix, Inc. (OCUL) News

Ocular Therapeutix, Inc. (OCUL): $5.32

-0.18 (-3.27%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add OCUL to Watchlist
Sign Up

Industry: Biotech


Ranked

of 402

in industry

Filter OCUL News Items

OCUL News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

OCUL News Highlights

  • OCUL's 30 day story count now stands at 4.
  • Over the past 12 days, the trend for OCUL's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • The most mentioned tickers in articles about OCUL are EYE, AGE and AMD.

Latest OCUL News From Around the Web

Below are the latest news stories about Ocular Therapeutix Inc that investors may wish to consider to help them evaluate OCUL as an investment opportunity.

Theravance Biopharma (TBPH) Reports Q4 Loss, Lags Revenue Estimates

Theravance Bio (TBPH) delivered earnings and revenue surprises of -43.33% and 4.14%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 23, 2022

Ocular Therapeutix To Report Fourth Quarter and Year-End 2021 Financial Results

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (Nasdaq: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will report fourth quarter and year-end financial results on Monday, February 28, 2022, after the market close. Following distribution of the earnings release via wire services, the Ocular Therapeutix management team will host a live conference

Business Wire | February 22, 2022

Ocular Therapeutix™ To Report Fourth Quarter and Year-End 2021 Financial Results

BEDFORD, Mass., February 22, 2022--Ocular Therapeutix™, Inc. (Nasdaq: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will report fourth quarter and year-end financial results on Monday, February 28, 2022, after the market close. Following distribution of the earnings release via wire services, the Ocular Therapeutix management team will host a live conference

Yahoo | February 22, 2022

Ocular Therapeutix™ Announces Upcoming Presentation of Interim OTX-TKI Phase 1 Clinical Trial Data at Angiogenesis, Exudation, and Degeneration 2022 Meeting and OTX-TIC Phase 1 Clinical Trial at Glaucoma 360

BEDFORD, Mass., February 11, 2022--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced its intention to present data at two medical meetings. Data from the Phase 1 Australian-based clinical trial of OTX-TKI, an axitinib intravitreal implant for the treatment of patients with wet age-related macular degeneration (wet AMD) and other retinal

Yahoo | February 11, 2022

Ocular Therapeutix owner buys 50,000 shares worth ~$300K (NASDAQ:OCUL)

Ocular Therapeutix <> 10% owner, Summer Road LLC, bought 50,000 shares of the company in a price range of $5.78-6.45, worth ~$300K.This brings his total share holding to

Seeking Alpha | January 19, 2022

AffaMed Therapeutics begins dosing in China trial of DEXTENZA to treat ocular inflammation

Ocular Therapeutix <> said AffaMed Therapeutics dosed its first patient in a real-world setting study being conducted in China to evaluate the safety and efficacy of DEXTENZA (0.4

Seeking Alpha | January 18, 2022

AffaMed Therapeutics, licensee of DEXTENZA® in Certain Asian Markets, Doses Their First Patient in Clinical Trial Evaluating the Safety and Efficacy of DEXTENZA® in China in Cataract Surgery Patients

BEDFORD, Mass., January 18, 2022--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that AffaMed Therapeutics dosed its first patient in a real-world setting study being conducted in China evaluating the safety and efficacy of DEXTENZA® (0.4 mg dexamethasone ophthalmic insert) for the treatment of ocular inflammation and pain post-catara

Yahoo | January 18, 2022

Hikari Power Ltd Buys Alphabet Inc, Vanguard Health Care ETF, Bristol-Myers Squibb Co, Sells ...

Tokyo, M0, based Investment company Hikari Power Ltd (Current Portfolio) buys Alphabet Inc, Vanguard Health Care ETF, Bristol-Myers Squibb Co, Jack Henry & Associates Inc, Parker Hannifin Corp, sells Anheuser-Busch InBev SA/NV, The Kraft Heinz Co, Amarin Corp PLC, ADMA Biologics Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Hikari Power Ltd.

Yahoo | January 12, 2022

Ocular Therapeutix: Shaken By Covid, Perfectly Positioned For Long-Term Gains

No summary available.

Seeking Alpha | January 7, 2022

Ocular Therapeutix™ to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference

BEDFORD, Mass., January 04, 2022--Ocular Therapeutix, Inc. (Nasdaq: OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will present at the H.C. Wainwright BioConnect 2022 Virtual Conference being held January 10-13, 2022.

Yahoo | January 4, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5869 seconds.